Functionalization of iron oxide magnetic nanoparticles with targeting ligands: Their physicochemical properties and in vivo behavior

Nanomedicine

Volumn 5, Issue 9, 2010, Pages 1357-1369

  Fang, Chen ^a   Veiseh, Omid ^a   Kievit, Forrest ^a   Bhattarai, Narayan ^a   Wang, Freddy ^a   Stephen, Zach ^a   Li, Chun ^b   Lee, Donghoon ^c   Ellenbogen, Richard G ^c   Zhang, Miqin ^a,c  

^a University of Washington   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

bioconjugation; cancer; chlorotoxin; glioma; magnetic resonance imaging; nanoparticle; nanotechnology; RGD peptide; stability; targeting

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; BETA3 INTEGRIN; GELATINASE A; MACROGOL; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCOMPATIBILITY; CELL CULTURE; DRUG DISTRIBUTION; IN VIVO STUDY; MOUSE; NANOPROBE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ANIMALS; CELL LINE, TUMOR; FERRIC COMPOUNDS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MAGNETICS; MICE; MICE, NUDE; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, TRANSMISSION; MICROSCOPY, FLUORESCENCE; NANOPARTICLES; OLIGOPEPTIDES;

EID: 78650052719     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.10.55     Document Type: Article

References (43)

1. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R: Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751-760 (2007).
2. Sun C, Lee JSH, Zhang M: Magnetic nanoparticles in MR imaging and drug delivery. Adv. Drug Deliv. Rev. 60, 1252 (2008).
3. Weissleder R, Pittet MJ: Imaging in the era of molecular oncology. Nature 452, 580-589 (2008).
4. Cai WB, Chen XY: Nanoplatforms for targeted molecular imaging in living subjects. Small 3, 1840-1854 (2007).
5. Fang C, Zhang M: Multifunctional magnetic nanoparticles for medical imaging applications. J. Mater. Chem. 19, 6258-6266 (2009).
6. Weissleder R: Molecular imaging in cancer. Science 312, 1168-1171 (2006).
7. Waldman AD, Jackson A, Price SJ et al.: Quantitative imaging biomarkers in neuro-oncology. Nat. Rev. Clin. Oncol. 6, 445-454 (2009).
8. Fang C, Bhattarai N, Sun C, Zhang M: Functionalized nanoparticles with long-term stability in biological media. Small 5, 1637-1641 (2009).
9. Nel AE, Mädler L, Velegol D et al.: Understanding biophysicochemical interactions at the nano-bio interface. Nat. Mater. 8, 543-557 (2009).
10. Lewinski N, Colvin V, Drezek R: Cytotoxicity of nanoparticles. Small 4, 26-49 (2008).
11. Lorusso G, Ruegg C: The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem. Cell Biol. 130, 1091-1103 (2008).
12. 3 for angiogenesis. Science 264, 569-571 (1994).
13. Hood JD, Cheresh DA: Role of integrins in cell invasion and migration. Nat. Rev. Cancer 2, 91-100 (2002).
14. Overall CM, Kleifeld O: Tumour microenvironment-opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer 6, 227-239 (2006).
15. Stetler-Stevenson WG: Progelatinase A activation during tumor cell invasion. Invasion Metastasis 14, 259-268 (1994).
16. 5 in ocular neovascular diseases. Proc. Natl Acad. Sci. USA 93, 9764-9769 (1996).
17. Gurrath M, Muller G, Kessler H, Aumailley M, Timpl R: Conformation activity studies of rationally designed potent antiadhesive RGD peptides. Eur. J. Biochem. 210, 911-921 (1992).
18. Cai W, Chen X: Multimodality molecular imaging of tumor angiogenesis. J. Nucl. Med. 49(Suppl. 2), S113-S128 (2008).
19. Cai W, Chen X: Preparation of peptide-conjugated quantum dots for tumor vasculature-targeted imaging. Nat. Protoc. 3, 89-96 (2008).
20. Montet X, Funovics M, Montet-Abou K, Weissleder R, Josephson L: Multivalent effects of RGD peptides obtained by nanoparticle display. J. Med. Chem. 49, 6087-6093 (2006).
21. De La Zerda A, Zavaleta C, Keren S et al.: Carbon nanotubes as photoacoustic molecular imaging agents in living mice. Nature Nanotech. 3, 557-562 (2008).
22. Chen H, Wang L, Yeh J et al.: Reducing non-specifc binding and uptake of nanoparticles and improving cell targeting with an antifouling PEO-b-PgMPS copolymer coating. Biomaterials 31(20), 5397-5407 (2010).
23. Chen W, Jarzyna PA, van Tilborg GA et al.: RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe. FASEB J. 24(6), 1689-1699 (2010).
24. Danhier F, Vroman B, Lecouturier N et al.: Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel. J. Control. Release. 140, 166-173 (2009).
25. Deshane J, Garner CC, Sontheimer H: Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2. J. Biol. Chem. 278, 4135-4144 (2003).
26. Veiseh O, Sun C, Gunn J et al.: Optical and MRI multifunctional nanoprobe for targeting gliomas. Nano Lett. 5, 1003-1008 (2005).
27. McFerrin MB, Sontheimer H: A role for ion channels in glioma cell invasion. Neuron Glia Biol. 2, 39-49 (2006).
28. Veiseh O, Gunn J W, Kievit FM et al.: Inhibition of tumor-cell invasion with chlorotoxin-bound superparamagnetic nanoparticles. Small 5, 256-264 (2009).
29. Park J, An K, Hwang Y et al.: Ultra-large-scale syntheses of monodisperse nanocrystals. Nat. Mater. 3, 891-895 (2004).
30. Schellenberger EA, Sosnovik D, Weissleder R, Josephson L: Magneto/optical annexin V, a multimodal protein. Bioconjug. Chem. 15, 1062-1067 (2004).
31. Riemer J, Hoepken HH, Czerwinska H, Robinson SR, Dringen R: Colorimetric ferrozine-based assay for the quantitation of iron in cultured cells. Anal. Biochem. 331, 370-375 (2004).
32. Sun C, Veiseh O, Gunn J et al.: In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes. Small 4, 372-379 (2008).
33. Meyer A, Auernheimer J, Modlinger A, Kessler H: Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr. Pharm. Des. 12, 2723-2747 (2006).
34. Pouchert CJ: The Aldrich Library of FT-IR Spectra. Aldrich Chemical Co., Milwaukee, WI, USA (1985).
35. Wrensch M, Minn Y, Chew T, Bondy M, Berger MS: Epidemiology of primary brain tumors: current concepts and review of the literature. J. Neurooncol. 4, 278-299 (2002).
36. Montet X, Montet-Abou K, Reynolds F, Weissleder R, Josephson L: Nanoparticle imaging of integrins on tumor cells. Neoplasia. 8, 214-222 (2006).
37. Veiseh M, Gabikian P, Bahrami SB et al.: Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res. 67, 6882-6888 (2007).
38. Petri-Fink A, Steitz B, Finka A, Salaklang J, Hofmann H: Effect of cell media on polymer coated superparamagnetic iron oxide nanoparticles (SPIONs): colloidal stability, cytotoxicity, and cellular uptake studies. Eur. J. Pharm. Biopharm. 68, 129-137 (2008).
39. Albini A, Sporn MB: The tumour microenvironment as a target for chemoprevention. Nat. Rev. Cancer. 7, 139-147 (2007).
40. Bibby DC, Talmadge JE, Dalal MK et al.: Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice. Int. J. Pharm. 293, 281-290 (2005).
41. Jacoby DB, Dyskin E, Yalcin M et al.: Potent pleiotropic anti-angiogenic effects of TM601, a synthetic chlorotoxin peptide. Anticancer Res. 30, 39-46 (2010).
42. Kesavan K, Ratliff J, Johnson EW et al.: Annexin A2 is a molecular target for TM601, a peptide with tumor-targeting and anti-angiogenic effects. J. Biol. Chem. 285, 4366-4374 (2010).
43. Sontheimer H: An unexpected role for ion channels in brain tumor metastasis. Exp. Biol. Med. (Maywood). 233, 779-791 (2008).